KCNIP4 rs145489027: ACE Inhibitor-Induced Cough Risk
The rs145489027 variant is a single-nucleotide polymorphism located within the KCNIP4 gene. Research has identified this variant as being associated with an increased risk of developing a persistent dry cough as a side effect of taking ACE inhibitor medications.
What each genotype means
Typical cough risk
This genotype represents the common version of the KCNIP4 gene variant. Research indicates that individuals with this genotype do not carry the specific genetic marker associated with an increased risk of ACE inhibitor-induced cough. Please discuss any concerns regarding medication side effects with your clinician or pharmacist.
This is the most common genotype in many populations, though exact frequencies vary by ancestry.
Increased cough risk
Carrying one copy of the A allele is associated with a statistically higher likelihood of developing a dry cough when taking ACE inhibitor medications. This association was identified in large-scale genomic studies, though the underlying biological mechanism remains unknown. Please consult your healthcare provider or pharmacist if you experience persistent cough while on this medication.
This genotype is found in a significant portion of the population, with the minor allele (A) having a frequency of approximately 33% in diverse cohorts.
Higher cough risk
Carrying two copies of the A allele is associated with an increased risk of developing a dry cough as a side effect of ACE inhibitor therapy compared to those without the variant. While this genetic association is statistically significant, it does not guarantee that you will experience this side effect. Please discuss your medication options and any side effects with your doctor or pharmacist.
This genotype is less common than the GG or GA genotypes, occurring at a frequency consistent with the minor allele frequency of approximately 33%.
Understanding the Variant and Its Location
The variant rs145489027 is a specific change in the DNA sequence located on chromosome 4. It sits within an intron of the KCNIP4 gene, which stands for Kv Channel Interacting Protein 4. Introns are non-coding regions of a gene that do not provide direct instructions for building proteins but can play significant roles in regulating how genes are expressed. Because this variant is located in a regulatory region, researchers have investigated whether it influences the function of the KCNIP4 protein or the surrounding genetic environment. While the exact biological mechanism remains a subject of ongoing study, its position within this gene has made it a primary focus for scientists exploring why some individuals experience adverse reactions to common blood pressure medications.
The Role of the KCNIP4 Gene
The KCNIP4 gene encodes a protein that acts as a regulatory subunit for Kv4 potassium channels. These channels are essential for controlling the electrical activity of cells, particularly in the heart and the nervous system. By modulating the flow of potassium ions, KCNIP4 helps maintain the stability and proper signaling of these cells. In the context of ACE inhibitor-induced cough, scientists hypothesize that the gene may influence sensory nerve endings in the lungs. Since ACE inhibitors are known to affect pathways involving bradykinin—a substance that can trigger cough when it accumulates in the respiratory tract—the interaction between KCNIP4-regulated channels and these nerve pathways is a leading area of interest for understanding why some patients develop this specific, often bothersome, side effect.
Evidence and Research Findings
The association between rs145489027 and ACE inhibitor-induced cough was first identified through a large-scale genome-wide association study (GWAS) involving thousands of participants. This study found that individuals carrying the minor allele of this variant had a statistically higher likelihood of reporting a cough while on ACE inhibitor therapy. However, the strength of this evidence is considered moderate. While some studies have replicated these findings in different cohorts, others have reported mixed results, suggesting that the effect may vary depending on the population studied or other environmental factors. Because of these inconsistencies, the current scientific consensus is that there is insufficient evidence to support using this variant as a definitive clinical tool for predicting drug reactions. It remains a candidate for further research rather than a standard diagnostic marker.
Clinical Implications and Patient Guidance
It is important to understand that having a specific genotype for rs145489027 does not guarantee that you will or will not experience a cough while taking an ACE inhibitor. Genetic markers are only one piece of a complex puzzle that includes your overall health, other medications, and individual biology. If you are currently taking an ACE inhibitor and are concerned about a persistent cough, do not make any changes to your medication regimen based on genetic information alone. Always consult with your physician or pharmacist before adjusting your treatment. They can evaluate your symptoms, review your medical history, and determine if a different class of blood pressure medication, such as an ARB, might be a more appropriate alternative for your specific health needs.
How common is this variant?
The rs145489027 variant is considered rare, with the minor allele frequency reported at approximately 0.33 in large study cohorts, though frequencies can vary across different ancestral backgrounds.
Frequently asked questions
Does having the 'A' allele mean I will definitely get a cough from ACE inhibitors?
No. Genetic associations indicate a statistical trend across large groups of people, not a certainty for an individual. Many people with the 'A' allele take ACE inhibitors without experiencing any cough at all.
Should I get a genetic test for this variant before starting blood pressure medication?
Currently, there is no clinical recommendation to test for this variant before starting ACE inhibitor therapy. The evidence is not strong enough to make it a standard part of medical practice.
What should I do if I have a cough while taking an ACE inhibitor?
You should contact your healthcare provider to discuss your symptoms. They can determine if the cough is a side effect of the medication or caused by another health issue and may suggest switching to a different type of medication.
Is KCNIP4 involved in other health conditions?
KCNIP4 is primarily known for its role in regulating potassium channels, which are important for cardiac and neurological function. Research into its broader role in human health is ongoing.
Sources & further reading
Educational information only, last refreshed 10/31/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs145489027?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29